{"DataElement":{"publicId":"3265290","version":"1","preferredName":"Colon Adenocarcinoma No Prior Second Line Treatment Ind-2","preferredDefinition":"the yes/no indicator related to no prior second preferred therapy for an adenocarcinoma arising from the colon.","longName":"3265289v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3265289","version":"1","preferredName":"Colon Adenocarcinoma No Prior Second Line Treatment","preferredDefinition":"information related to no prior second preferred therapy for an adenocarcinoma arising from the colon.","longName":"3091415v1.0:3265287v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3091415","version":"1","preferredName":"Colon Adenocarcinoma","preferredDefinition":"An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well differentiated, moderately, and poorly differentiated.  Morphologic variants include the mucinous adenocarcinoma and signet-ring adenocarcinoma.  Lymphatic or hematogenous spread can occur early in the process and lead to systemic disease.","longName":"C4349","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colon Adenocarcinoma","conceptCode":"C4349","definition":"An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87207F38-B7DE-9EDD-E040-BB89AD431C38","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"ONEDATA","dateModified":"2010-05-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3265287","version":"1","preferredName":"No Prior Second Line Treatment","preferredDefinition":"The non-affirmative response to a question.:Earlier in time or order.:The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.\r\n","longName":"C49487:C25629:C54350","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Second-Line Therapy","conceptCode":"C54350","definition":"The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABB2447E-BEAC-F980-E040-BB89AD434C01","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-30","modifiedBy":"ONEDATA","dateModified":"2011-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABB2447E-BEBD-F980-E040-BB89AD434C01","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"No prior second-line systemic","type":"Preferred Question Text","description":"No prior second-line systemic treatment for metastatic colon adenocarcinoma. Patients who received prior adjuvant therapy for colon adenocarcinoma and/or prior first-line systemic therapy for metastatic colon adenocarcinoma are eligible","url":null,"context":"CTEP"}],"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ABB2447E-BECF-F980-E040-BB89AD434C01","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-30","modifiedBy":"DWARZEL","dateModified":"2012-07-18","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}